Literature DB >> 18465347

BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer.

Mads Thomassen1, Thomas V O Hansen, Ake Borg, Henriette Theilmann Lianee, Friedrik Wikman, Inge Søkilde Pedersen, Marie Luise Bisgaard, Finn C Nielsen, Torben A Kruse, Anne-Marie Gerdes.   

Abstract

A national study of BRCA1 and BRCA2 mutations in Danish HBOC (Hereditary Breast Ovarian Cancer) families revealed a total number of 322 mutation positive families, 206 (64%) BRCA1 and 116 (36%) BRCA2 positive families from a population of 5.5 million inhabitants. Seven hundred and twenty six mutation positive individuals were identified: 402 female BRCA1 carriers, 79 male BRCA1 carriers, 213 female BRCA2 carriers, and 32 male BRCA2 carriers by April 2006. Most of the mutations were frame shift or nonsense mutations, while large genomic rearrangements were rare. Most mutations were only identified in one family. A few mutations were detected repeatedly. In BRCA1 the most common mutations were: 2594delC in 32 families (16%), 3438G>T in 19 families (9%), 5382insC in 16 families (8%), 3829delT in 11 families (5%). In BRCA2 the most common mutations were: 6601delA in 13 families (11%), 1538del4 in 12 families (10%), 6714del4 in 10 families (9%). There was a tendency towards a higher frequency of BRCA2 mutations in West Denmark compared to East Denmark. The frequencies of specific BRCA1 and BRCA2 mutations were slightly different in the two regions. The mutations occurring in West Denmark have also been observed in other Scandinavian countries whereas the mutations occurring in East Denmark were more often reported from other European countries and the Baltic countries. The pattern of mutation distributions are comparable with observations from other Scandinavian and European studies and indicate that the Danish BRCA1 and BRCA2 mutations are a mixture of Scandinavian mutations and other European mutations including two of the Ashkenazi mutations. Even though a tendency towards founder mutations was observed most mutations were only detected once. Based on these observations we recommend that the mutation screening strategy of the BRCA1 and BRCA2 genes in Danish HBOC families comprises full screening of both genes including analysis for large genomic rearrangements.

Entities:  

Mesh:

Year:  2008        PMID: 18465347     DOI: 10.1080/02841860802004974

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  18 in total

Review 1.  Common BRCA1 and BRCA2 mutations in breast cancer families: a meta-analysis from systematic review.

Authors:  Furu Wang; Qiaoqiao Fang; Zhen Ge; Ningle Yu; Sanxiao Xu; Xiangyong Fan
Journal:  Mol Biol Rep       Date:  2011-06-04       Impact factor: 2.316

2.  Novel germline mutations in BRCA2 gene among breast and breast-ovarian cancer families from Poland.

Authors:  Aneta Balabas; Elzbieta Skasko; Dorota Nowakowska; Anna Niwinska; Pawel Blecharz
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

3.  Screening of 1331 Danish breast and/or ovarian cancer families identified 40 novel BRCA1 and BRCA2 mutations.

Authors:  Thomas V O Hansen; Lars Jønson; Ane Y Steffensen; Mette K Andersen; Susanne Kjaergaard; Anne-Marie Gerdes; Bent Ejlertsen; Finn C Nielsen
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

4.  Identification of a Danish breast/ovarian cancer family double heterozygote for BRCA1 and BRCA2 mutations.

Authors:  Ane Y Steffensen; Lars Jønson; Bent Ejlertsen; Anne-Marie Gerdes; Finn C Nielsen; Thomas V O Hansen
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

5.  A high frequent BRCA1 founder mutation identified in the Greenlandic population.

Authors:  Theresa Larriba Harboe; Hans Eiberg; Peder Kern; Bent Ejlertsen; Lotte Nedergaard; Vera Timmermans-Wielenga; Inge-Merete Nielsen; Marie Luise Bisgaard
Journal:  Fam Cancer       Date:  2009-06-07       Impact factor: 2.375

6.  BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population.

Authors:  Henriette Roed Nielsen; Mef Nilbert; Janne Petersen; Steen Ladelund; Mads Thomassen; Inge Søkilde Pedersen; Thomas V O Hansen; Anne-Bine Skytte; Åke Borg; Christina Therkildsen
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

7.  Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study.

Authors:  Ake Borg; Robert W Haile; Kathleen E Malone; Marinela Capanu; Ahn Diep; Therese Törngren; Sharon Teraoka; Colin B Begg; Duncan C Thomas; Patrick Concannon; Lene Mellemkjaer; Leslie Bernstein; Lina Tellhed; Shanyan Xue; Eric R Olson; Xiaolin Liang; Jessica Dolle; Anne-Lise Børresen-Dale; Jonine L Bernstein
Journal:  Hum Mutat       Date:  2010-03       Impact factor: 4.878

8.  Germline BRCA1 mutations increase prostate cancer risk.

Authors:  D Leongamornlert; N Mahmud; M Tymrakiewicz; E Saunders; T Dadaev; E Castro; C Goh; K Govindasami; M Guy; L O'Brien; E Sawyer; A Hall; R Wilkinson; D Easton; D Goldgar; R Eeles; Z Kote-Jarai
Journal:  Br J Cancer       Date:  2012-05-08       Impact factor: 7.640

9.  New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing.

Authors:  Anna Kluska; Aneta Balabas; Agnieszka Paziewska; Maria Kulecka; Dorota Nowakowska; Michal Mikula; Jerzy Ostrowski
Journal:  BMC Med Genomics       Date:  2015-05-07       Impact factor: 3.063

10.  Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.

Authors:  Ramūnas Janavičius
Journal:  EPMA J       Date:  2010-06-27       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.